In this episode, we discuss updates on low-risk MDS with Dr. Maximilian Stahl with a focus on imetelstat and luspatercept.  Here are the trials we discussed:  1. IWG 2019 response criteria<a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042664/">https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042664/</a> 2. MEDALIST trial: Luspatercept<a href="https://www.nejm.org/doi/10.1056/NEJMoa1908892?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed">https://www.nejm.org/doi/10.1056/NEJMoa1908892?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%20%200pubmed</a> 3. COMMANDS trial : Luspatercept <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00874-7/abstract">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00874-7/abstract</a><a href="https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00203-5/abstract">https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00203-5/abstract</a> 4. IMerge trial: Imetelstat <a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01724-5/abstract">https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01724-5/abstract</a>

<description>
 &lt;p&gt;In this episode, we discuss updates on low-risk MDS with Dr. Maximilian Stahl with a focus on imetelstat and luspatercept. &lt;br&gt;Here are the trials we discussed: &lt;br&gt;1. IWG 2019 response criteria&lt;/p&gt;&lt;p&gt;&lt;a href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042664/"&gt;https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7042664/&lt;/a&gt; &lt;/p&gt;&lt;p&gt;2. MEDALIST trial: Luspatercept&lt;/p&gt;&lt;p&gt;&lt;a href="https://www.nejm.org/doi/10.1056/NEJMoa1908892?url_ver=Z39.88-2003&amp;amp;rfr_id=ori:rid:crossref.org&amp;amp;rfr_dat=cr_pub%20%200pubmed"&gt;https://www.nejm.org/doi/10.1056/NEJMoa1908892?url_ver=Z39.88-2003&amp;amp;rfr_id=ori:rid:crossref.org&amp;amp;rfr_dat=cr_pub%20%200pubmed&lt;/a&gt; &lt;/p&gt;&lt;p&gt;3. COMMANDS trial : Luspatercept &lt;/p&gt;&lt;p&gt;&lt;a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00874-7/abstract"&gt;https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)00874-7/abstract&lt;/a&gt;&lt;/p&gt;&lt;p&gt;&lt;a href="https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00203-5/abstract"&gt;https://www.thelancet.com/journals/lanhae/article/PIIS2352-3026(24)00203-5/abstract&lt;/a&gt; &lt;/p&gt;&lt;p&gt;4. IMerge trial: Imetelstat &lt;/p&gt;&lt;p&gt;&lt;a href="https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01724-5/abstract"&gt;https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01724-5/abstract&lt;/a&gt;&lt;/p&gt;&lt;p&gt; &lt;/p&gt;&lt;p&gt; &lt;/p&gt;
 </description>

Blood Cancer Talks

Episode 49. Updates on Low-Risk MDS with Dr. Maximilian Stahl

Episode 49. Updates on Low-Risk MDS with Dr. Maximilian Stahl

Description